Plant ID: NPO23933
Plant Latin Name: Gymnosporia diversifolia
Taxonomy Genus: Gymnosporia
Taxonomy Family: Celastraceae
NCBI TaxonomyDB:
490239
Plant-of-the-World-Online:
n.a.
PIK3CB; PIK3CA; GFER; NQO2; | |
CA2; CA14; CA12; CA9; | |
ESR1; | |
PTGS2; |
Cytochrome P450 Enzymes: | CYP3A4; |
---|
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.744E-11 | 1.686E-06 | CA12, CA14, CA2, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.636E-09 | 8.314E-05 | CA12, CA14, CA2, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.709E-07 | 4.228E-03 | CA12, CA2, CA9 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.174E-10 | 1.151E-08 | CA12, CA2, CA9, CA14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 3.377E-06 | 1.430E-04 | PIK3CA, PIK3CB, PTGS2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 4.378E-06 | 1.430E-04 | PIK3CA, PIK3CB, PTGS2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 7.230E-06 | 1.771E-04 | PIK3CA, PIK3CB, ESR1 |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.235E-05 | 2.422E-04 | PIK3CA, PIK3CB, PTGS2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.886E-05 | 3.081E-04 | PIK3CA, PIK3CB, ESR1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 2.587E-05 | 3.621E-04 | PIK3CA, PIK3CB, PTGS2 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 3.191E-05 | 3.909E-04 | PIK3CA, PIK3CB, ESR1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 7.619E-05 | 8.296E-04 | PIK3CA, PIK3CB, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.601E-04 | 1.569E-03 | PIK3CA, PIK3CB, ESR1 |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 4.167E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 2.015E-04 | 1.795E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 3.060E-04 | 2.306E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 3.592E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 4.317E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 2.688E-04 | 2.195E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 4.784E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 5.613E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 5.108E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 5.442E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 5.787E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 6.142E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 5.787E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.963E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.138E-03 | 3.111E-03 | PIK3CA, PIK3CB, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 6.694E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 7.075E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 7.075E-04 | 2.391E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 6.694E-04 | 2.391E-03 | CA2, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.049E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.003E-03 | 3.071E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.270E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 8.072E-04 | 2.637E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.169E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04666 | Fc gamma R-mediated phagocytosis | 1.145E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.348E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.270E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.917E-04 | 2.819E-03 | CYP3A4, PTGS2 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04070 | Phosphatidylinositol signaling system | 1.270E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 1.348E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 1.322E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.402E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.625E-03 | 3.318E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.483E-03 | 3.160E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.429E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 1.429E-03 | 3.111E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 1.568E-03 | 3.269E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.833E-03 | 3.572E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 1.958E-03 | 3.621E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.895E-03 | 3.572E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 1.833E-03 | 3.572E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.895E-03 | 3.572E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 2.287E-03 | 3.991E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 2.022E-03 | 3.669E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.321E-03 | 3.991E-03 | PIK3CA, PIK3CB |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.567E-03 | 4.125E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.321E-03 | 3.991E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 2.390E-03 | 4.028E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 2.425E-03 | 4.028E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.788E-03 | 4.269E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 2.531E-03 | 4.125E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 2.713E-03 | 4.221E-03 | PIK3CA, PIK3CB |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 2.640E-03 | 4.173E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 2.978E-03 | 4.422E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.863E-03 | 4.317E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 3.255E-03 | 4.761E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 3.975E-03 | 5.646E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 3.628E-03 | 5.228E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 5.258E-03 | 7.058E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 4.524E-03 | 6.334E-03 | PIK3CA, PIK3CB |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.258E-03 | 7.058E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 5.107E-03 | 7.049E-03 | PIK3CA, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 5.411E-03 | 7.166E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 5.723E-03 | 7.477E-03 | PIK3CA, PIK3CB |
09140 Cellular Processes | 09142 Cell motility | hsa04810 | Regulation of actin cytoskeleton | 5.882E-03 | 7.584E-03 | PIK3CA, PIK3CB |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 6.594E-03 | 8.392E-03 | PIK3CA, PIK3CB |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
NA: NA | Menopausal disorder | NA | ESR1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
NA: NA | Joint and muscular pain | NA | PTGS2; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; PTGS2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; NQO2; CA9; |
NA: NA | Rheumatold arthritis | NA | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
NA: NA | Edema | NA | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; PIK3CB; CA9; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIK3CA; PTGS2; PIK3CB; NQO2; CA9; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |